Type
Buy
Instrument
CADILAHC OCT20 380 CE
Entry Price
₹24.25
Price@Trade
₹24.25
Target Price
₹200
Stop Price
₹2
Valid Till
Oct 29, 2020 3:20 AM
Margin
₹53,350 approx for 2200 Qty
Status
Active
FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
Find answers to all your questions on live CADILAHC message board: Is CADILAHC buy or sell? Should I buy CADILAHC shares? Why are CADILAHC shares falling? Should I invest in CADILAHC stock?
forum
CADILAHC Share Price Discussion
Cadila Healthcare Ltd.
NSE: CADILAHC | BSE: 532321 | ISIN: INE010B01027 | Sector: Pharmaceuticals and health care
N
Reputation: 6,184 • Aug 14 2:33 AM
How do pharma companies get volunteers for COVID-19 vaccine trials, what are the risks, and other questions answered
The Clinical Trial Registry - India (CTRI) website is the principal source of getting to know about various clinical trials
The Clinical Trial Registry - India (CTRI) website is the principal source of getting to know about various clinical trials
Moneycontrol
Like
Reply
NSE:CADILAHC price when posted: 386
Recent posts in CADILAHC
Zydus Cadila gets USFDA nod for multiple sclerosis treatment drug
Zydus Cadila has received final approval from the United States Food and Drug Administration (USFDA) to market Dimethyl Fumarate delayed release capsules, (Tecfidera) in the strengths of 120 mg and 240 mg, Zydus Cadila, part of Cadila Healthcare group, said in a regulatory filing.
Zydus Cadila has received final approval from the United States Food and Drug Administration (USFDA) to market Dimethyl Fumarate delayed release capsules, (Tecfidera) in the strengths of 120 mg and 240 mg, Zydus Cadila, part of Cadila Healthcare group, said in a regulatory filing.
Moneycontrol
Like
Reply
N
Reputation: 6,184 • Yesterday 5:06 AM
Zydus Cadila gets tentative USFDA nod to market anti-cancer drug
Drug firm Zydus Cadila on Thursday said it has received tentative approval from the US health regulator to market anti-cancer drug Palbociclib Capsules.
Drug firm Zydus Cadila on Thursday said it has received tentative approval from the US health regulator to market anti-cancer drug Palbociclib Capsules.
The Economic Times
Like
Reply